Harvard Bioscience
HBIO
91 hedge funds and large institutions have $14.5M invested in Harvard Bioscience in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 37 reducing their positions, and 12 closing their positions.
25% more call options, than puts
Call options by funds: $5K | Put options by funds: $4K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.3% less ownership
Funds ownership: 7.12% → 5.82% (-1.3%)
4% less funds holding
Funds holding: 95 → 91 (-4)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
41% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 37
78% less capital invested
Capital invested by funds: $65.5M → $14.5M (-$51M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AE
AMH Equity
Great Neck,
New York
|
+$1.14M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$334K |
| 3 |
RC
RBF Capital
San Francisco,
California
|
+$232K |
| 4 |
Renaissance Technologies
New York
|
+$223K |
| 5 |
Squarepoint
New York
|
+$218K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
-$3.5M |
| 2 |
2C
272 Capital
Dallas,
Texas
|
-$2.85M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$2.43M |
| 4 |
HP
Harvey Partners
Tarrytown,
New York
|
-$634K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$422K |
HBIO Hedge Fund Activity: Q1 2025 in Review
91 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2025, worth a combined $14.5M — down 78% from $65.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of HBIO and 9 opened new positions — a net loss of 3 holders — while 37 trimmed existing stakes and 22 added.
The largest buyer was AMH Equity, adding an estimated $1.14M. The largest seller was Punch & Associates Investment Management, cutting an estimated $3.5M.
- 91 institutional investors held Harvard Bioscience (HBIO) as of Q1 2025, down from 95 in Q4 2024.
- Funds reported $14.5M of Harvard Bioscience stock for Q1 2025, down 78% quarter-over-quarter.
- 9 funds opened new Harvard Bioscience positions in Q1 2025 and 12 closed out, a net change of -3 holders.
- The largest Harvard Bioscience buyer in Q1 2025 was AMH Equity, an estimated $1.14M added.
- The largest Harvard Bioscience seller in Q1 2025 was Punch & Associates Investment Management, an estimated $3.5M sold.
Based on aggregated 13F filings for Q1 2025.